MKK4 inhibitor 3-benzoyl-1H-pyrrolo[2,3-B]pyridine derivatives for the treatment of liver diseases

By developing selective MKK4 inhibitor compounds, the problem of poor effect of MKK4 inhibitors in the prior art was solved, high selective inhibition of MKK4 was achieved, hepatocyte regeneration and reduced hepatocyte death, and significantly improved liver function recover.

CN114981267BActive Publication Date: 2024-11-08HEPAREGENIX GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180009123.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-01-15
Filing Date
2021-01-13
Publication Date
2024-11-08
Estimated Expiration
2041-01-13

AI Technical Summary

Technical Problem

Existing MKK4 inhibitors are not effective in clinical treatment of liver diseases, and it is particularly difficult to selectively inhibit MKK4 without affecting JNK1 and MKK7, and cannot effectively promote hepatocyte regeneration or reduce hepatocyte death.

Method used

A selective MKK4 inhibitor compound was developed to inhibit MKK4 by a specific chemical structure (Formula (I)), which includes a combination of specific groups to ensure high selectivity to MKK4 and is used to treat liver disease to promote Hepatocyte regeneration or reduces hepatocyte death.

Benefits of technology

This compound significantly increased the proliferation rate of hepatocytes, reduced liver damage and steatosis, improved liver regeneration ability and functional recovery, and showed effective liver protection effects in preclinical mouse models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114981267B_ABST
    Figure CN114981267B_ABST
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I) as MKK4 (mitogen-activated protein kinase kinase 4) inhibitors and their use in promoting liver regeneration or reducing or preventing liver cell death. These compounds selectively inhibit protein kinase MKK4 relative to protein kinases JNK1 and MKK7. In formula (I), in particular, R w NR 10 S02R 12 or a) R x and R y is F and R z and R zz is H; or b) R x , R y and R zz are independently halogen and R z H; R 5 It is a substituted phenyl or pyrimidinyl. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to protein kinase inhibitors that inhibit mitogen-activated protein kinase kinase 4 (MKK4), in particular selectively inhibiting MKK4 relative to protein kinases JNK1 and MKK7. Background Art

[0002] Liver disease can be caused by infection, injury, exposure to toxic compounds (such as alcohol or drugs), autoimmune processes, genetic defects, and other factors. The liver has a remarkable regenerative capacity, which, however, can be impaired in disease states and, therefore, may be insufficient to compensate for the loss of liver cells and organ function.

[0003] WO 2007 / 002433 describes compounds that are protein kinase inhibitors useful for treating diseases and conditions associated with abnormal activity of protein kinases. These compounds are inhibitors of Raf protein kinases, particularly B-Raf and c-Raf and mutations thereof, and are therefore useful for cancer treatment. In addition, they are said to inhibit a variety of other protein kinases, including c-Jun N-terminal kinase (JNK), especially JNK1. WO 2010 / 002325 has similar disclosures, and WO 2012 / 109075 and WO 2014 / 194127 disclose modified compounds with Raf protein kinase inhibitory activity. H. Vin et al. refer to the two compounds of WO2007 / 002433 as B-Raf inhibitors that inhibit apoptosis by off-target inhibition of JNK signaling. WO 2010 / 111527 describes pyrazolo[3,4-b]pyridine compounds that are protein kinase inhibitors useful for treating diseases or conditions mediated by Raf protein kinases, such as cancer. In addition, it is said that they can inhibit a variety of other protein kinases, including c-Jun N-terminal kinase (JNK), especially JNK1. WO2012 / 136859 discloses some compounds, which are described as inhibitors of mitogen-activated protein kinase kinase 4 (MKK4) and can be used to treat liver failure, protect liver cells from apoptosis and for the regeneration of liver cells. Wuestefeld et al. (Cell 153: 389-401, 2013) describe a functional genetics method for identifying gene targets that can be used to improve the regeneration capacity of liver cells. In particular, Wuestefeld et al. identified protein kinase MKK4 as a key regulator of liver regeneration, and reported that MKK4 inhibition increases liver cell regeneration via compensatory upregulation of MKK7 and JNK1-dependent activation of ATF2 and ELK1. Based on the findings of the prior art, it has been concluded that MKK4 and JNK1 inhibitors can be used to treat JNK1-mediated diseases.

[0004] However, it has been recognized that these compounds have failed in the treatment of liver diseases in clinical practice. Summary of the invention

[0005] The problem underlying the present invention is to provide useful compounds which are MKK4 inhibitors, in particular MKK4 inhibitors which selectively inhibit MKK4 relative to JNK1 and MKK7. Another problem is to provide compounds which are MKK4 inhibitors which selectively inhibit MKK4 relative to JNK1 and MKK7 and which can be used to treat liver diseases, in particular to promote liver regeneration or reduce or prevent liver cell death.

[0006] This problem is solved by providing compounds of formula (I).

[0007] Therefore, the present invention relates to the following embodiments:

[0008] 1. A compound of formula (I), and pharmaceutically acceptable salts, solvates and optical isomers thereof,

[0009]

[0010] R 1 is H or alkyl;

[0011] R 2 is H or alkyl;

[0012] R 4 is H or alkyl;

[0013] R 6 is H or alkyl;

[0014] R w For-NR 10 S02R 12 ;

[0015] R 10 is H, alkyl or phenylalkyl;

[0016] R 12 is H, alkyl or phenylalkyl, wherein the phenyl group is optionally substituted with 1 or 2 groups independently selected from alkyl and halogen;

[0017] R x , R y , R z and R zz Selected from:

[0018] a) R x and R y For F, R z and R zz is H; and

[0019] b) R x , R y and R zz are independently halogen and R z is H;

[0020] R 5 Selected from

[0021] (a) phenyl substituted by 1, 2 or 3 groups independently selected from -PO di(alkyl) and hydroxyalkyl-ONH-CO-;

[0022] (b) pyrimidinyl substituted by 1, 2 or 3 groups independently selected from alkyl, cycloalkyl, alkoxy and sulfonyl.

[0023] 2. The compound according to Embodiment 1, and its pharmaceutically acceptable salts, solvates and optical isomers, wherein R 5 is phenyl substituted with 1 or 2 groups independently selected from -PO di(alkyl) and hydroxyalkyl-ONH-CO-.

[0024] 3. The compound according to Embodiment 1, and its pharmaceutically acceptable salts, solvates and optical isomers, wherein R 5 is pyrimidinyl substituted by 1 or 2 groups independently selected from alkyl, cycloalkyl, alkoxy and alkylsulfonyl.

[0025] 4. A compound according to Embodiment 3, and pharmaceutically acceptable salts, solvates and optical isomers thereof, wherein the pyrimidinyl group is bound to 1H-pyrrolo[2,3-b]pyridine at the 5-position, is substituted at the 2-position by an alkyl, cycloalkyl or alkoxy group, and is optionally substituted at the 4-position by an alkyl or alkylsulfonyl group.

[0026] 5. The compound according to Embodiment 4, and pharmaceutically acceptable salts, solvates and optical isomers thereof, wherein the pyrimidinyl group is bound to 1H-pyrrolo[2,3-b]pyridine at the 5-position and is substituted with a cycloalkyl group or an alkyl group at the 2-position.

[0027] 6. The compound according to Embodiment 3, and pharmaceutically acceptable salts, solvates and optical isomers thereof, wherein the pyrimidinyl group is bound to 1H-pyrrolo[2,3-b]pyridine at the 5-position and is substituted by an alkyl group at the 4-position or at the 2-position and the 4-position, wherein the alkyl groups at the 4-position and at the 6-position may be the same or different.

[0028] 7. The compound according to any one of the preceding embodiments, and its pharmaceutically acceptable salts, solvates and optical isomers, wherein R 12 is C1-C4-alkyl or phenylalkyl, the phenylalkyl being in particular benzyl.

[0029] 8. The compound according to embodiment 7, and its pharmaceutically acceptable salts, solvates and optical isomers, wherein R 12 is C1-C4-alkyl, preferably methyl, ethyl or propyl.

[0030] 9. A compound of formula (Ia) according to any one of the preceding embodiments, and pharmaceutically acceptable salts, solvates and optical isomers thereof,

[0031]

[0032] Where R 1 , R 2 , R 4 , R 5 , R 6 , R x , R w and R y As defined in any one of embodiments 1 to 8.

[0033] 10. A compound of formula (Ib) according to any one of the preceding embodiments 1-8, and pharmaceutically acceptable salts, solvates and optical isomers thereof,

[0034]

[0035] Where R 1 , R 2 , R 4 , R 5 , R 6 , R x , R w , R y and R ZZ As defined in any one of embodiments 1 to 8.

[0036] 11. A compound according to any one of the preceding embodiments, wherein R 1 , R 2 , R 3 , R 4 and R 6 is H or alkyl, especially H.

[0037] 12. A compound according to any one of the preceding embodiments, wherein R 10 is H or alkyl, especially H. DETAILED DESCRIPTION

[0038] In one embodiment, the present invention relates to selective MKK4 inhibitor compounds and pharmaceutically acceptable salts, solvates and optical isomers thereof, wherein the compounds have Formula I, wherein R 1 To R6 , R 10 , A and Q in any combination are as defined in the above embodiments.

[0039] In one embodiment, the compounds of the invention and pharmaceutically acceptable salts, solvates and optical isomers thereof selectively inhibit protein kinase MKK4 relative to protein kinases JNK and MKK7.

[0040] In addition, the present invention also relates to the use of the compound in promoting liver regeneration or reducing or preventing liver cell death while increasing liver cell proliferation.

[0041] The term "compound of the present invention" or "compound of formula (I)" includes pharmaceutically acceptable salts, prodrugs, biologically active metabolites, solvates and stereoisomers thereof.

[0042] The present invention includes pharmaceutically acceptable salts of the above compounds. Pharmaceutically acceptable salts are in particular acid addition salts or base addition salts with pharmaceutically acceptable acids or bases. Examples of suitable pharmaceutically acceptable organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, aminosulfonic acid, C1-C4-alkylsulfonic acids, such as methanesulfonic acid, alicyclic sulfonic acids, such as S-(+)-10-camphorsulfonic acid, aromatic sulfonic acids, such as benzenesulfonic acid and toluenesulfonic acid, dicarboxylic acids and tricarboxylic acids and hydroxycarboxylic acids having 2 to 10 carbon atoms, such as oxalic acid, malonic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, glycolic acid, adipic acid and benzoic acid. Other available acids are described, for example, in Fortschritte der Arzneimittelforschung [Advances indrug research (Advances in drug research)], volume 10, pages 224 et seq., Verlag, Basel and Stuttgart, 1966. Examples of suitable pharmaceutically acceptable organic and inorganic bases are alkali metal hydroxides such as sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides such as calcium hydroxide or magnesium hydroxide, ammonium hydroxide, organic nitrogen bases such as dimethylamine, trimethylamine, ethanolamine, diethanolamine, triethanolamine, choline, 2-amino-2-hydroxymethyl-propane-1,3-diol, meglumine, procaine and the like, L-arginine, L-lysine, ethylenediamine or hydroxyethylpyrrolidine.

[0043] The present invention also includes any tautomeric, crystalline and polymorphic forms of the compounds and salts of the present invention and mixtures thereof.

[0044] The present invention also includes solvates, such as hydrates.

[0045] The compounds of the present invention may contain one or more chiral centers and exist in different optically active forms, such as enantiomers and diastereomers.

[0046] As used herein, the term "prodrug" refers to an agent that is converted into the parent drug in vivo by some physiological and chemical process. A non-limiting example of a prodrug is a compound of the invention in the form of an ester.

[0047] Prodrugs have many useful properties. For example, a prodrug may be more soluble in water than the final drug, thereby facilitating intravenous administration of the drug. A prodrug may also have a higher level of oral bioavailability than the final drug. After administration, the prodrug is enzymatically or chemically cleaved to deliver the final drug to the blood or tissues. Exemplary prodrugs include, but are not limited to, compounds having a carboxylic acid substituent in which the free hydrogen is replaced by a group such as (C1-C4)alkyl, (C1-C 12 )alkanoyloxy-methyl, (C4-C9)1-(alkanoyloxy)ethyl, 1-methyl-1-(alkanoyloxy)-ethyl having 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having 3 to 6 carbon atoms, 1-(alkoxycarbonyl-oxy)ethyl having 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)-ethyl having 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)methyl having 4 to 10 carbon atoms )ethyl, 3-phthalidyl, 4-crotono-lactonyl, γ-butyrolactone-4-yl, di-N,N-(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)-alkylcarbamoyl-(C1-C2)alkyl and piperidinyl-, pyrrolidinyl- or morpholinyl(C2-C3)alkyl. Other exemplary prodrugs release alcohols of Formula (I) in which the free hydrogen of the hydroxy substituent (e.g., the R group contains a hydroxyl group) is replaced by a group consisting of: (C1-C6)alkanoyloxy-methyl, 1-((C1-C6)alkanoyloxy)-ethyl, 1-methyl-1-((C1-C6)alkanoyloxy)ethyl, (C1-C 12)alkoxy-carbonyloxy-methyl, N-(C1-C6)-alkoxy-carbonylaminomethyl, succinyl, (C1-C6)alkanoyl, α-amino(C1-C4)alkanoyl, aryllactyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, wherein the α-aminoacyl moieties are independently any naturally occurring L-amino acid found in proteins, P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2 or a glycosyl (a free radical generated by the detachment of the hydroxyl group of a carbohydrate hemiacetal).

[0048] The expression "MKK4 inhibitor" means that after administration, the kinase activity of MKK4 is inhibited, IC 50 <10 μmol / l, preferably <1 μmol / l, in particular <0.5 μmol / l. As used herein, the expression "selectively inhibits protein kinase MKK4 relative to protein kinases JNK1 and MKK7" refers to the use of KINOMEscan TM When measured, expressed as a percentage of Kd or control, the ratio of MKK7 inhibitory activity to MKK4 inhibitory activity or the ratio of JNK1 inhibitory activity to MKK4 inhibitory activity was ≥10.

[0049] As used herein, the expression "promoting liver regeneration or reducing or preventing liver cell death" means that the relative number of proliferating liver cells increases by at least 30%, preferably at least 50%, compared to the number of proliferating cells at the beginning of treatment. In particular, the expression means an increase of ≥100% compared to the number of proliferating cells at the beginning of treatment. In this case, the experimental determination and quantification will be performed using standard methods, such as the quantification of the protein Ki67, which is closely related to cell proliferation. For the quantification of proliferating liver cells in tissue slides, there are several standard immunohistochemical methods available, which use a primary anti-Ki67 antibody and then visualize the anti-Ki67 binding by using, for example, a horseradish peroxidase-conjugated secondary antibody. The amount of peroxidase activity visualized by enzymatic conversion of a chromogenic substrate is related to the amount of Ki67 protein and the number of proliferating cells.

[0050] In the experiments described below, hepatocyte proliferation was quantified by Ki67 staining using a primary polyclonal rabbit anti-Ki67 antibody from Abcam (Cat. No. ab15580, Abcam, Cambridge, USA) and a secondary goat polyclonal antibody from Invitrogen containing the fluorophore tetramethylrhodamine (Cat. No. 16101, Invitrogen / ThermoFisher). Based on data obtained from several preclinical mouse models, it was found that in a mouse model of chronic CCl4 (carbon tetrachloride)-mediated liver injury, shRNA (small hairpin RNA)-mediated inhibition of MKK4 increased hepatocyte proliferation from 13% to 27% (compared to control shRNA) and was associated with reduced liver damage (transaminases) and reduced liver fibrosis. The relative increase in proliferating cells was 108% as defined in the previous section. In a model of alcohol-induced steatohepatitis (ASH), shRNA-mediated silencing of MKK4 resulted in a hepatocyte proliferation rate of 4%, compared to 2% when control shRNA was used (relative increase: 100%). Doubling of hepatocyte proliferation was associated with reduced liver damage measured by transaminases and reduced steatosis (fat deposition). Similarly, in a partial hepatectomy model (48 hours after surgical removal of two-thirds of the liver), shRNA-mediated silencing of MKK4 increased hepatocyte proliferation from 16% (control shRNA) to 33% (relative increase: 106%). Again, increased hepatocyte proliferation was associated with improved liver regeneration and faster recovery of liver mass.

[0051] The organic moieties mentioned in the definitions of the above variables - such as the term halogen - are collective terms for the individual listed items of the individual group members. n -C m In each case the possible number of carbon atoms in the group is indicated.

[0052] The term halogen denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine or chlorine.

[0053] Alkyl is a straight-chain or branched alkyl group, preferably a C1-C6-alkyl group, ie an alkyl group having 1 to 6 carbon atoms, more preferably a C1-C4-alkyl group. Examples of the alkyl group are methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.

[0054] The definition of alkyl applies equally to any group including an alkyl group.

[0055] Cycloalkyl is an alicyclic radical, preferably a C3-C8-cycloalkyl, i.e. a cycloalkyl having 3 to 8 carbon atoms. In particular, 3 to 6 carbon atoms form a ring structure, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The ring structure may be unsubstituted or may carry 1, 2, 3 or 4 C1-C4 alkyl, preferably one or more methyl radicals.

[0056] Compounds of the present invention, including pharmaceutically acceptable salts, prodrugs, bioactive metabolites, solvates and stereoisomers thereof, can be prepared as disclosed in WO 2007 / 002433, which is incorporated herein by reference or as a whole according to similar procedures. Acid addition salts or base addition salts are prepared in a conventional manner by mixing a free base with a corresponding acid or by mixing a free acid with a desired base. Alternatively, the reaction is carried out in a solution of an organic solvent, such as a lower alcohol, such as methanol, ethanol or propanol, an ether, such as methyl tert-butyl ether or diisopropyl ether, a ketone, such as acetone or methyl ethyl ketone, or an ester, such as EtOAc.

[0057] The compounds of the present invention can be used to promote liver regeneration or reduce or prevent liver cell death while increasing liver cell proliferation. Therefore, these compounds can be used to treat, regulate, improve or prevent diseases involving acute or chronic liver damage, which may be caused by infection, injury, exposure to toxic compounds, abnormal accumulation of normal substances in the blood, autoimmune processes, genetic defects or unknown causes.

[0058] This class of liver diseases includes all diseases in which increasing liver regeneration and reducing or preventing hepatocyte death may help achieve a potential therapeutic effect, i.e. partial or complete restoration of liver function. These diseases include:

[0059] Acute and chronic or acute on chronic liver diseases, such as acute and chronic viral hepatitis, e.g. hepatitis B, hepatitis C, hepatitis E, hepatitis caused by Epstein-Barr virus, cytomegalovirus, herpes simplex virus or other viruses, various autoimmune hepatitis, primary sclerosing hepatitis, alcoholic hepatitis;

[0060] Metabolic liver diseases, such as metabolic syndrome, fatty liver such as non-alcoholic fatty liver disease (NAFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), Wilson's disease (Morbus Wilson), hemochromatosis, alpha 1-antitrypsin deficiency, glycogen storage diseases;

[0061] Various types of liver cirrhosis, such as primary biliary cirrhosis, ethyl toxic liver cirrhosis, cryptogenic cirrhosis;

[0062] Acute (fulminant) or chronic liver failure, such as toxic liver failure, e.g., liver failure caused by acetaminophen (paracetamol), liver failure caused by alpha-amanitin, drug-induced liver toxicity, liver failure, e.g., liver toxicity caused by antibiotics, nonsteroidal anti-inflammatory drugs, anticonvulsants, acute liver failure caused by herbal supplements (kava, ephedra, skullcap, pennyroyal, etc.), liver disease and failure due to vascular disease such as Budd-Chiari syndrome, acute liver failure of unknown cause, chronic liver disease caused by right heart failure;

[0063] Galactosemia, cystic fibrosis, porphyria, ischaemic perfusion injury, small for size syndrome after liver transplantation, primary sclerosing cholangitis, or hepatic encephalopathy.

[0064] In order to promote liver regeneration or reduce or prevent liver cell death, the compounds of the present invention are administered to patients in need in a therapeutically effective amount. There are a variety of diagnostic methods that can be used to detect the presence of liver disease. It is known that blood levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) above the clinically acceptable normal range indicate on-going liver damage. Blood bilirubin levels or other liver enzymes can be used as detection or diagnostic criteria. Routine monitoring of blood ALT and AST levels in patients with liver disease is used to measure the progression of liver disease during drug treatment. Reducing elevated ALT and AST levels to within an acceptable normal range is considered clinical evidence that reflects a reduction in the severity of liver damage in the patient. Commercial assays such as FibroTest / FibroSURE, FibroMeter or Cirrhometer evaluates the combined results of five or more biochemical parameters to detect hepatic steatosis, fibrosis and cirrhosis. In addition, non-invasive, innovative physical imaging techniques such as magnetic resonance imaging, ultrasonography, and especially elastography can be used to detect and monitor the status and progression of liver disease.

[0065] It was further found that shRNA-mediated inhibition of MKK4 attenuated TNF-α-driven cartilage matrix degradation in osteoarthritis (Cell Death and Disease (2017) 8, e3140). Therefore, the use of the compounds of the present invention to inhibit the activity of MKK4 can be further used to treat osteoarthritis and rheumatoid arthritis.

[0066] The compounds of the present invention are usually administered in the form of a pharmaceutical composition comprising at least one compound according to the present invention, optionally together with an inert carrier (e.g., a pharmaceutically acceptable excipient), and other drugs (where appropriate). For example, these compositions can be administered orally, rectally, transdermally, subcutaneously, intraperitoneally, intravenously, intramuscularly or intranasally.

[0067] Examples of suitable pharmaceutical compositions are solid pharmaceutical forms, such as powders, granules, tablets, in particular film tablets, lozenges, sachets, cachets, sugar-coated tablets, capsules, such as hard and soft gelatin capsules, or suppositories, semisolid pharmaceutical forms, such as ointments, creams, hydrogels, pastes or plasters, and liquid pharmaceutical forms, such as solutions, emulsions, in particular oil-in-water emulsions, suspensions, for example lotions, injections and infusions. In addition, liposomes or microspheres may also be used.

[0068] When preparing compositions, the compounds according to the present invention are optionally mixed or diluted with one or more carriers (excipients). A carrier (excipient) can be a solid, semisolid or liquid material used as a vehicle, carrier or medium for the active compound.

[0069] Suitable carriers (excipients) are listed in professional pharmaceutical monographs. In addition, the preparation may contain pharmaceutically acceptable auxiliary substances, such as wetting agents; emulsifiers and suspending agents; preservatives; antioxidants; antiirritants; chelating agents; coating aids; emulsion stabilizers; film formers; gel formers; odor masking agents; taste correctors; resins; hydrocolloids; solvents; solubilizers; neutralizers; diffusion accelerators; pigments; quaternary ammonium compounds; refatting agents and overfatting agents; raw materials for ointments, creams or oils; silicone derivatives; dispersing aids; stabilizers; bactericides; suppository bases; tablet aids, such as binders, fillers, glidants, disintegrants or coating agents; propellants; desiccants; opacifiers; thickeners; waxes; plasticizers and white mineral oil. The formulations in this regard are based on specialist knowledge, as described, for example, in Fiedler, HP, Lexikon der Hilfsstoffe für Pharmazie, Kosmetik undangrenzende Gebiete [Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields], 4th edition, Aulendorf: ECV-Editio-Cantor-Verlag, 1996.

[0070] The compounds of the present invention may also be suitable for combination with other therapeutic agents. Therefore, the present invention also relates to a combination comprising the compounds of the present invention and one or more other therapeutic agents, particularly for promoting liver regeneration or reducing or preventing liver cell death. The combined therapy of the present invention may be adjunctive administration. "Adjunctive administration" refers to the continuous or overlapping administration of each component in the form of a separate pharmaceutical composition or device. The therapeutic dosing regimen of the two or more therapeutic agents is generally referred to as adjunctive therapy administration by those skilled in the art and herein; it is also referred to as add-on therapy administration. Any and all therapeutic regimens in which the patient receives separate but continuous or overlapping therapeutic administration of the compounds of the present invention and at least one additional therapeutic agent are within the scope of the present invention. In one embodiment of adjunctive therapy administration as described herein, the patient is generally stabilized on the therapeutic administration of one or more components for a period of time, and then receives administration of another component.

[0071] The combination therapy of the present invention can also be administered simultaneously. Simultaneous administration refers to a treatment regimen in which the components are administered together in the form of a single pharmaceutical composition or device containing all components or as different compositions or devices each containing one component. This combination of different individual components for simultaneous combination can be provided in the form of a kit.

[0072] Agents suitable for use in combination with the compounds of the present invention include, for example:

[0073] ACC inhibitors, such as TOFA (5-(tetradecyloxy)-2-furoic acid), firsocostat (formerly known as GS0976),

[0074] PF-05221304 and ACC inhibitors as disclosed in WO 2016 / 112305,

[0075] Angiotensin II receptor antagonists,

[0076] Angiotensin-converting enzyme (ACE) inhibitors, such as enalapril,

[0077] ASK1 (apoptosis signal-regulating kinase 1, MAP3K5) inhibitors, such as selonsertib (formerly known as GS-4997) or SRT-015,

[0078] Caspase inhibitors, such as emricasan,

[0079] Cathepsin B inhibitors, such as mixed cathepsin B / hepatitis C virus NS3 protease inhibitors, such as VBY-376,

[0080] CCR2 chemokine antagonists, such as mixed CCR2 / CCR5 chemokine antagonists, such as cenicriviroc,

[0081] CCR5 chemokine antagonists,

[0082] Chloride channel stimulators, such as cobiprostone,

[0083] Cholesterol solubilizer,

[0084] Copperamine oxidase 3 (AOC3) inhibitors, such as BI 1467335 (formerly PXS-4728A),

[0085] Diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors, such as LCQ908 or GSK-3008356,

[0086] Diacylglycerol O-acyltransferase 2 (DGAT2) inhibitors, such as PF-06865571,

[0087] Dipeptidyl peptidase IV (DPPIV) inhibitors, such as linagliptin,

[0088] Farnesoid X receptor (FXR) agonists, such as INT-747 (obeticholic acid), cliofexor (formerly GS-9674 or PX-102), tropifexor (formerly LJN452), EDP-305, or LMB-763,

[0089] Fibroblast growth factor (FGF) and its analogs, such as long-acting analogs of FGF19 (e.g. aldafermin, formerly known as NGM-282) or long-acting analogs of FGF21 (e.g. TEV-47948, also known as Bio89-100, or ARK01 or PF-05231023),

[0090] FXR / TGR5 dual agonists, such as INT-767,

[0091] Galectin 3 inhibitors, such as GR-MD-02,

[0092] Glucagon-like peptide 1 (GLP1) agonists, such as liraglutide or exenatide,

[0093] Glucagon-like peptide 1 (GLP1) / glucagon dual agonists, such as cotadutide,

[0094] Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, such as tirzepatide (formerly known as LY3298176),

[0095] Glutathione precursor,

[0096] Hepatitis C virus NS3 protease inhibitors, such as mixed cathepsin B / hepatitis C virus NS3 protease inhibitors, such as VBY-376,

[0097] HMG CoA reductase inhibitors, such as statins, such as atorvastatin,

[0098] 11β-Hydroxysteroid dehydrogenase (11β-HSD1) inhibitors, such as R05093151,

[0099] IL-1β antagonists,

[0100] IL-6 antagonists, such as mixed IL-6 / IL-1β / TNFα ligand inhibitors, such as BLX-1002,

[0101] IL-10 agonists, such as peg-ilodecakin,

[0102] Anti-IL-11 antibody or IL-11 antagonist,

[0103] IL-17 antagonists, such as KD-025,

[0104] Ileal sodium bile acid transporter inhibitors, such as volixibat (formerly SHP-626),

[0105] Integrin inhibitors, such as selective αvβ1-inhibitors (e.g. PLN-1474 or those reviewed in Wilkinson et al., Eur. J. Pharmacol., 842, 239-247 (2019)),

[0106] Ketohexokinase inhibitors, such as PF-06835919,

[0107] Leptin analogs, such as metreleptin,

[0108] 5-lipoxygenase inhibitors, such as mixed 5-lipoxygenase / PDE3 / PDE4 / PLC inhibitors, such as tipelukast,

[0109] LPL gene stimulators, such as alipogene tiparvovec,

[0110] Lysyl oxidase homolog 2 (LOXL2) inhibitors, such as anti-LOXL2 antibodies, such as simtuzumab (

[0111] formerly known as GS-6624), or small molecule inhibitors such as those disclosed in WO 2017 / 136870,

[0112] Small molecule inhibitors of the nod-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome, such as MCC950,

[0113] ω-3 polyunsaturated fatty acids and their derivatives, such as icosabutate and the examples disclosed in US 8,735,436 B2,

[0114] Oxysterol sulfates, such as 25-hydroxycholesterol 3-sulfate and 25-hydroxy-cholesterol 3,25-disulfate,

[0115] PDE4 inhibitors, such as ASP-9831

[0116] PPARα agonists, such as the mixed PPARα / δ agonist elafibranor (formerly known as GFT-505), the mixed PPARα / γ / δ agonist lanibibranor or the mixed PPARα / γ agonist saroglitazar),

[0117] PPARγ agonists, such as pioglitazone,

[0118] PPARδ agonists, such as seladelpar,

[0119] Rho-associated protein kinase 2 (ROCK2) inhibitors, such as KD-025,

[0120] Sodium glucose transporter-2 (SGLT2) inhibitors, such as remogliflozin etabonate,

[0121] Sodium glucose transporter-1 / 2 (SGLT1 / 2) inhibitors, such as licogliflozin

[0122] Stearoyl CoA desaturase-1 inhibitors, such as aramchol or CVT-12805,

[0123] Thyroid hormone receptor beta agonists, such as MGL-3196 or VK2809,

[0124] Tumor necrosis factor alpha (TNFα) ligand inhibitors,

[0125] Transglutaminase inhibitors and transglutaminase inhibitor precursors, such as mercaptoethylamine,

[0126] PTPlb inhibitors, such as A119505, A220435, A321842, CPT633, ISIS-404173, JTT-551, MX-7014, MX-7091, MX-7102, NNC-521246, OTX-001, OTX-002 or TTP814, and Namacizumab, are antibodies that stabilize the cannabinoid type 1 receptor (CB1) in an inactive conformation.

[0127] In some embodiments, the one or more additional therapeutic agents are selected from acetylsalicylic acid, alipokine, aramchol, atorvastatin, BLX-1002, cenikvir, cobiprostone, colesevelam, enlicasen, enalapril, GFT-505, GR-MD-02, hydrochlorothiazide, icosapentaenoic acid ethyl (ethyl eicosapentaenoic acid), IMM-124E, KD-025, linagliptin, liraglutide, mercaptoethylamine, MGL-3196, obeticholic acid, olesoxime, polyethylene glycol-ilovucin, pioglitazone, GS-9674, repagliflozin ectoate, SHP-626, solithromycin, tipelukast, TRX-318, ursodeoxycholic acid, and VBY-376.

[0128] In some embodiments, one of the one or more additional therapeutic agents is selected from acetylsalicylic acid, alipokine, aramchol, atorvastatin, BLX-1002, and cenikvir.

[0129] In one embodiment, the invention relates to a method for

[0130] Inhibits protein kinase MKK4,

[0131] Selective inhibition of protein kinase MKK4 relative to protein kinases JNK1 and MKK7 promotes liver regeneration or prevents hepatocyte cell death.

[0132] Treatment of acute, acute-on-chronic or chronic liver disease,

[0133] Treatment of acute and chronic or acute-on-chronic liver diseases, such as acute and chronic viral hepatitis, such as hepatitis B, hepatitis C, hepatitis E, hepatitis caused by Epstein-Barr virus, cytomegalovirus, herpes simplex virus or other viruses, all types of autoimmune hepatitis, primary sclerosing hepatitis, alcoholic hepatitis;

[0134] Treatment of metabolic liver diseases such as metabolic syndrome, fatty liver such as non-alcoholic fatty liver disease (NAFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), Wilson's disease, hemochromatosis, alpha 1-antitrypsin deficiency, glycogen storage disease;

[0135] Treatment of all types of cirrhosis, such as primary biliary cirrhosis, alcoholic cirrhosis, cryptogenic cirrhosis; treatment of acute (fulminant) or chronic liver failure, such as toxic liver failure, such as liver failure caused by acetaminophen (paracetamol), liver failure caused by alpha-amanitin, drug-induced liver toxicity and liver failure, such as liver toxicity and liver failure caused by antibiotics, nonsteroidal anti-inflammatory drugs, anticonvulsants, acute liver failure caused by herbal supplements (kava, ephedra, skullcap, mint, etc.), liver disease and failure due to vascular disease such as Budd-Chiari syndrome, acute liver failure of unknown cause, chronic liver disease caused by right heart failure;

[0136] Treatment of galactosemia, cystic fibrosis, porphyria, hepatic ischemic perfusion injury, small liver syndrome after liver transplantation, primary sclerosing cholangitis, or hepatic encephalopathy, or

[0137] Treat osteoarthritis or rheumatoid arthritis,

[0138] The method comprises administering to a subject in need thereof an effective amount of a compound or composition as defined above.

[0139] In one embodiment, the compounds of the invention are administered at a dose of 0.2 to 15 mg / kg or 0.5 to 12 mg / kg relative to the subject being treated. The compounds can be administered once or several times a day. The administration period of these compounds is 4 to 12 weeks.

[0140] The following examples illustrate the invention without limiting it.

[0141] Example

[0142] abbreviation

[0143] ATP Adenosine triphosphate

[0144] DCM Dichloromethane

[0145] 4-DMAP 4-Dimethylaminopyridine

[0146] DMA Dimethylacetamide

[0147] DMF Dimethylformamide

[0148] DMSO Dimethyl sulfoxide

[0149] DPPA Diphenylphosphorylazide

[0150] DTT Dithiothreitol

[0151] EtOH

[0152] EtOAc Ethyl acetate

[0153] FCC fast column chromatography

[0154] HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethanesulfonic acid

[0155] HOBt Hydroxybenzotriazole

[0156] HPLC High Performance Liquid Chromatography

[0157] IPA isopropyl alcohol (or iPrOH)

[0158] LCMS Liquid chromatography mass spectrometry

[0159] MeCN Acetonitrile

[0160] MeOH Methanol

[0161] NaHCO3 Sodium bicarbonate

[0162] NBS N-Bromosuccinimide

[0163] NMP N-Methylpyrrolidone

[0164] NMR Nuclear Magnetic Resonance

[0165] Pd(dppf)Cl2 [1,1'-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride

[0166] PE Petroleum Ether

[0167] rt or RT Room temperature

[0168] TEA Triethanolamine

[0169] TFA Trifluoroacetic acid

[0170] THF Tetrahydrofuran

[0171] TLC Thin Layer Chromatography

[0172] Example

[0173] Example 01: Synthesis of 2,4-difluoro-3-nitrobenzoic acid

[0174] Chemical formula: C7H3F2NO4 (MW: 203.10)

[0175]

[0176] Step 1: Synthesis of 1-bromo-2,4-difluoro-3-nitrobenzene

[0177] To a stirred solution of 1,3-difluoro-2-nitrobenzene (1 eq. (equivalent), 50.0 g, 314.29 mmol) in H2SO4 (400 mL) was added NBS (1.20 eq., 67.12 g, 377.14 mmol) and the reaction mixture was heated to 80 ° C for 16 hours. The reaction was monitored by TLC (100% hexane), and after completion, the reaction mixture was poured into ice-cold water and extracted with EtOAc (2 L). The organic layer was separated and washed with saturated NaHCO3 solution and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by FCC (gradient 1-5% EtOAc in n-hexane) to give a yellow liquid 1-bromo-2,4-difluoro-3-nitrobenzene (50 g, 67%).

[0178] Analyze the data: 1 H NMR (400MHz, CDCl3) δ7.78-7.71(m,1H),7.09-7.03(m,1H).

[0179] Step 2: Synthesis of methyl 3-amino-2,4-difluorobenzoate

[0180] The solution of 1-bromo-2,4-difluoro-3-nitrobenzene (1eq., 60.0g, 252.21mmol) in MeOH (1000mL) was degassed with nitrogen for 15 minutes. TEA (5eq., 127.49g, 1261.03mmol) was added and the reaction mixture was degassed for 5 minutes. Pd (dppf) Cl2 x DCM (0.10eq., 20.58g, 25.22mmol) was added and the reaction mixture was rinsed with carbon monoxide twice. Under carbon monoxide (200psi), the reaction mixture was stirred at room temperature for 30 minutes and further heated to 100°C for 12 hours. The reaction was monitored by TLC (100%DCM). After completion, the reaction mixture was filtered through a diatomaceous earth pad and volatiles were removed under reduced pressure. Crude ether was added and stirred at room temperature for 30 minutes, filtered through a pad of celite and the volatiles were removed under reduced pressure to give methyl 3-amino-2,4-difluorobenzoate (38.0 g, crude) as a yellow syrup.

[0181] Analyze the data:1 H NMR(400MHz,DMSO-d6)δ7.08-6.96(m,2H),5.46(s,2H),3.81(s,3H)

[0182] Step 3: Synthesis of methyl 2,4-difluoro-3-nitrobenzoate

[0183] 30%H2O2 (68.40mL) was stirred and TFA (205mL) solution of 3-amino-2,4-difluorobenzoic acid methyl ester (19.0g, 101.52mmol) was added dropwise at room temperature in 60 minutes. The reaction mixture was stirred at 80 ° C for 1 hour. The reaction was monitored by TLC (30% EtOAc in hexane). After completion, the reaction mixture was poured into crushed ice, the resulting precipitate was filtered and washed with water. The crude compound was vacuum dried to obtain 2,4-difluoro-3-nitrobenzoic acid methyl ester (19.0g, crude product) as a light brown solid, which was used for the next step reaction without any further purification.

[0184] Analyze the data: 1 H NMR (400MHz, DMSO-d6) δ8.30-8.21 (m, 1H), 7.62 (t, J = 9.29Hz, 1H), 3.90 (d, J = 0.98Hz, 3H).

[0185] Step 4: Synthesis of 2,4-difluoro-3-nitrobenzoic acid

[0186] At room temperature in 30 minutes to the solution of 2,4-difluoro-3-nitrobenzoic acid methyl ester (19.0g, 87.51mmol) in THF (200mL) stirred, add portion by portion LiOH x H2O (1.20eq., 4.40g, 105.01mmol) dissolved in H2O (100mL), and the reaction mixture is further stirred at room temperature for 3 hours. Monitor the reaction by TLC (10% MeOH in DCM). After completion, the reaction mixture is neutralized with 1N HCl solution and concentrated under reduced pressure. The obtained crude product is acidified with 1N HCl solution and extracted with EtOAc. Separate the organic layer, dry with anhydrous sodium sulfate, filter and concentrate under reduced pressure to obtain 2,4-difluoro-3-nitrobenzoic acid (15.50g, crude product) as off-white solid.

[0187] Analyze the data: 1 H NMR (400MHz, DMSO-d6) δ13.85(br s,1H),8.27-8.16(m,1H),7.62-7.53(m,1H).

[0188] Example 02: Synthesis of N-(3-(1-(2,6-dichlorobenzoyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide

[0189] Chemical formula: C 30 H 28 BCl2F2N3O6S(MW:678.34)

[0190]

[0191] Step 1: Synthesis of (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)(2,4-difluoro-3-nitrophenyl)methanone

[0192] Step 1a: 2,4-Difluoro-3-nitrobenzoic acid (12.4 g, 60.9 mmol) was suspended in nitromethane (50 ml, 20% of total volume), oxalyl chloride (5.44 mL, 63.4 mmol) and DMF (0.197 mL, 2.54 mmol) were added dropwise.

[0193] Step 1b: In a second flask, 5-bromo-1H-pyrrolo[2,3-b]pyridine (10 g, 50.8 mmol) and aluminum chloride (33.8 g, 254 mmol) were dissolved in nitromethane (204 ml, 80% of the total volume) and stirred for about 1 hour. The solution with in situ generated 2,4-difluoro-3-nitrobenzoyl chloride was added to the second flask within 10 minutes. The solution was stirred at 55 ° C overnight. TLC analysis showed that the reaction was complete. The mixture was cooled to 0 ° C, and after MeOH (102 ml) was added dropwise, the product began to precipitate. Water (169 ml) was added, the precipitate was filtered off and dried in vacuo. The product was obtained as a beige solid (15.2 g; 75% yield; 95% purity).

[0194] Analyze the data: 1 H NMR (400MHz, DMSO-d6) δ13.12(br s,1H),8.64(d,J=2.45Hz,1H),8.52-8.48(m,1H),8.38-8.34(m,1H),8.07-7.99(m,1H),7.64(t,J=9.29Hz,1H).

[0195] Step 2: Synthesis of (3-amino-2,4-difluorophenyl)(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone

[0196] (5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-(2,4-difluoro-3-nitrophenyl)methanone (15.1 g, 37.5 mmol) was suspended in EtOAc (659 mL) and THF (659 mL). The mixture was heated to 60 ° C and tin (II) chloride dihydrate (29.6 g, 131 mmol) was added in batches. After stirring for 2 days, TLC analysis showed that the reaction was complete. The mixture was cooled to room temperature and a half-saturated NaHCO3 solution was added. The precipitate was filtered off on sea sand and diatomaceous earth pads. The filtrate was washed with brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The solid was suspended in MeCN (50 ml), filtered and dried in vacuo. (3-Amino-2,4-difluorophenyl)-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone (11.9 g, 31.8 mmol, 85% yield) was obtained as a light orange solid.

[0197] Step 3: Synthesis of (3-(3-amino-2,4-difluorobenzoyl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-1-yl)(2,6-dichlorophenyl)methanone

[0198] TEA (4.65 mL, 33.3 mmol) was added to a solution of (3-amino-2,4-difluorophenyl)-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone (11.9 g, 31.7 mmol) in THF (338 mL) cooled in an ice bath. 2,6-dichlorobenzoyl chloride (4.60 mL, 32.1 mmol) was added dropwise, followed by 4-dimethylaminopyridine (0.194 g, 1.59 mmol). The ice bath was removed and the mixture was stirred at room temperature until the starting material was completely consumed. The solvent volume was reduced to about 1 / 10 volume, and the residue was diluted with EtOAc (500 ml). The organic phase was washed twice with 1M HCl (100 ml each time), once with brine (100 ml) and dried over sodium sulfate. The solvent was removed under reduced pressure and the residue was dissolved in THF (66 ml). n-Heptane (330 ml) was added in portions under vigorous stirring. After completion, stirring was continued at room temperature for 1 hour. The precipitate was filtered off and dried in vacuo. (3-amino-2,4-difluorophenyl)-[5-bromo-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (14.7 g, 26.5 mmol, 84% yield) was obtained as a beige solid.

[0199] Step 4: Synthesis of N-(3-(5-bromo-1-(2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide

[0200] Step 4a: To a cooled (-10°C, methanol / ice) solution of (3-amino-2,4-difluorophenyl)-[5-bromo-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (8.00 g, 14.5 mmol) in THF (76.2 mL) was added TEA (15.5 mL, 111 mmol). A solution of 1-propanesulfonyl chloride (3.58 mL, 31.8 mmol) in THF (3.6 mL) was added dropwise and the reaction mixture was stirred at -10°C until TLC showed completion.

[0201] Step 4b: 2N NaOH (8 eq., 61 mL) was added to the cold solution and the solution was warmed to room temperature. After TLC showed complete hydrolysis of the disulfonamide, the mixture was acidified with 1M HCl (pH=2) and extracted twice with EtOAc. The combined organic phase was dried over sodium sulfate and the solvent was removed in vacuo. The residue was dissolved in EtOAc (50 mL) and treated with n-pentane until no further precipitation was formed. The solid was filtered off and dried in vacuo (the main part of the product). The filtrate was concentrated under reduced pressure and purified by flash chromatography using PE / EE 30% as eluent (the second fraction of the product).

[0202] Step 5: (3-(3-amino-2,4-difluorobenzoyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(2,6-dichlorophenyl)methanone

[0203] To a stirred solution of (3-(3-amino-2,4-difluorobenzoyl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-1-yl)(2,6-dichlorophenyl)methanone (1 eq., 7.0 g, 13.33 mmol) in dry 1,4-dioxane (100 mL) was added bis(pinacolato)diboron (1.20 eq, 4.06 g, 16.00 mmol) followed by potassium acetate (molten, 2.50 eq, 3.28 g, 33.33 mmol). Pd(dppf)Cl2 x DCM (0.05 eq, 0.54 g, 0.67 mmol) was added to the mixed mixture and stirring was continued at 80 °C for 3 hours. The progress of the reaction was monitored by TLC (20% EtOAc in hexanes) and LC-MS. Upon completion, the reaction mixture was cooled to room temperature and filtered through a pad of celite. The resulting organic layer was concentrated under reduced pressure. The obtained crude product was dissolved in ether (200 mL), filtered and the organic layer was concentrated under reduced pressure. The crude product was triturated with acetonitrile and then filtered to obtain (3-(3-amino-2,4-difluorobenzoyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(2,6-dichlorophenyl)methanone 5 (7.0 g,) as a light brown solid.

[0204] Example 03: Synthesis of 4-(3-(2,4-difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

[0205] Step 1: Synthesis of 4-bromo-N-(2-hydroxyethoxy)benzamide

[0206]

[0207] 4-Bromobenzoyl chloride (1 eq., 0.200 mg, 0.91 mmol) was dissolved in dichloromethane (5 ml), triethylamine (4 eq., 0.262 mg, 3.64 mmol) was added, and then 2-(aminooxy)ethane-1-ol (1 eq., 0.070 mg, 0.91 mmol) was added. The reaction was monitored by TLC. After stirring at room temperature for 16 hours, the reaction mixture was poured into ice-cold water and extracted with DCM (10 ml). The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to give a crude compound. The crude compound was purified by column chromatography to give 4-bromo-N-(2-hydroxyethoxy)benzamide (0.120 g, 50%) 1H NMR(400MHz,DMSO-d6)δ11.85(s,1H),7.72(m,4H),4.76(s,1H),3.92(m,2H),3.60(m,2H)

[0208] LCMS: 260.80 [M+H] + ,261.80[M+H] + ,261.8[M+Na] + ,260.8[M+Na] +

[0209] Step 2: 4-(3-(2,4-difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

[0210]

[0211] N-(3-(1-(2,6-dichlorobenzoyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide (180 mg, 0.265 mmol), 4-bromo-N-(2-hydroxyethoxy)benzamide (75 mg, 290 mmol) and potassium fluoride (46.2 mg, 0.795 mmol) were suspended in 1,4-dioxane (0.9 mL) and water (0.45 mL) and degassed with argon for 5 minutes. Pd(dppf)Cl2 (8.09 mg, 0.0111 mmol) was added and the mixture was heated to 90°C for 6 hours. The solvent was evaporated and the residue was dissolved in 10 mL MeOH. Potassium carbonate (1 g) was added and the mixture was stirred at room temperature. After 6 hours, water was added and the pH was adjusted to ~7 with aqueous HCl (1 N). The aqueous phase was extracted 3 times with EtOAc, the combined organics were dried over sodium sulfate and the solvent removed in vacuo. The product was purified by preparative RP-HPLC.

[0212] Analyze the data:

[0213] 1H NMR(400MHz,DMSO-d6)δ12.94(s,1H),11.85(s,1H),9.66(s,1H),8.74(d, J=8.7Hz,2H),8.10(s,1H),7.89(dd,J=19.2,8.2Hz,4H),7.70–7.58(m,1H) ,7.35(t,J=8.7Hz,2H),4.79(t,J=5.6Hz,1H),3.95(t,J=4.6Hz,2H),3.69 –3.61(m,2H),3.18–3.10(m,2H),1.88–1.77(m,2H),1.00(t,J=7.4Hz,3H).

[0214] LC-MS: 559.20 [M+H] + .

[0215] Analogously to Examples 2 and 3, the following products were prepared:

[0216]

[0217]

[0218]

[0219]

[0220] *Commercially available 2,4,6-trifluoro-3-nitrobenzoic acid was used as the starting material.

[0221] Example 15: Biological Activity

[0222] 33Pan supplied by ProQinase GmbH, Freiburg, Germany was used. Assay Service measures the kinase activity of the compounds of the invention. ProQinase website ( https: / / www.proqinase.com / products- services-biochemical-assay-services / kinase-assays ) are disclosed in detail for the assay conditions. Briefly, all kinase assays were performed in 96-well FlashPlates from PerkinElmer (Boston, MA, USA). TM The reaction volume was 50 μl. The reaction mixture was pipetted in four steps in the following order:

[0223] 20 μl detection buffer (standard buffer)

[0224] 5 μl ATP solution (in H2O)

[0225] 5 μl test compound (in 10% DMSO)

[0226] 20 μl enzyme / substrate mixture

[0227] The assay for all protein kinases contained 70 mM HEPES-NaOH pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM sodium orthovanadate, 1.2 mM DTT, 50 μg / ml PEG20000, ATP (various concentrations, corresponding to the apparent ATP-Km of the corresponding kinase), [γ-33P]-ATP (approximately 8 x 1005 cpm per well), protein kinase and substrate.

[0228] The reaction mixture was incubated at 30°C for 60 minutes. The reaction was terminated with 50 μl of 2% (v / v) H3PO4, the plate was aspirated and washed twice with 200 μl of 0.9% (w / v) NaCl. The scintillation was determined using a microplate scintillation counter (Microbeta, Wallac). 33 Incorporation of Pi.

[0229] All assays were performed using the Beckman Coulter / SAGIANTM core system.

[0230] In the case of a single concentration assay, the potency of the test compound is expressed as % residual activity. To determine the IC50 value, serial dilutions with a final concentration range of 100 μM to 3 nM (10 concentrations) were tested. The fitting model for the IC50 assay was "S-shaped response (variable slope)", with the parameter "top" fixed at 100% and "bottom" fixed at 0%. The fitting method used was the least squares fit.

[0231] MKK4 Effect:

[0232]

[0233] The selectivity of the test compounds for BRaf, JNK1, and MKK7, collectively referred to as off-target, was calculated by the ratio of IC50 (off-target) / IC50 (MKK4) and categorized as follows:

[0234]

[0235] The results are given in Table 1 below.

[0236] Table 1: Based on the results of single concentration or IC 50 The inhibitory enzyme activity at the values ​​below 100 was shown, with representative examples showing biochemical potency against MKK4 and selectivity against BRaf, MKK7 and JNK1.

[0237]

[0238]

Claims

1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following:

2. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

3. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 2 for preparing a pharmaceutical composition for selectively inhibiting protein kinase MKK4 relative to protein kinases JNK1 and MKK7.

4. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 2 for preparing a pharmaceutical composition for promoting liver regeneration or preventing hepatocyte death.